E. Frair

E. Frair's research focuses on Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease, with an emphasis on developing and testing gene therapy approaches such as exon skipping, CRISPR/Cas9 gene editing, and AAV-based gene delivery to restore dystrophin protein production. Work spans mouse models, patient-derived cell lines, and early-phase clinical trials, alongside detailed characterization of DMD gene mutations and their molecular consequences.

Publication output grew from essentially none in 2017-2018 to a peak of 8 in 2021, with continued steady activity averaging under 5 papers per year over the last five years.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026